相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
Kohei Shitara et al.
LANCET ONCOLOGY (2019)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
Kenji Tamura et al.
LANCET ONCOLOGY (2019)
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
Jodi A. McKenzie et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
Jodi A. McKenzie et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model
Tomomi Nakayama Iwata et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Judith A. Seidel et al.
FRONTIERS IN ONCOLOGY (2018)
Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
Hiroji Iwata et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING- Dependent Pathway and Reinforce Antitumor Immunity
Yuichi Kitai et al.
JOURNAL OF IMMUNOLOGY (2017)
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
Toshihiko Doi et al.
LANCET ONCOLOGY (2017)
Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?
Hans-Peter Gerber et al.
BIOCHEMICAL PHARMACOLOGY (2016)
Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
Takashi Nakada et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
Yusuke Ogitani et al.
CANCER SCIENCE (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Chemotherapy and immunotherapy: mapping the road ahead
Alistair M. Cook et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Low dose of GRP78-targeting subtilase cytotoxin improves the efficacy of photodynamic therapy in vivo
Magdalena Gabrysiak et al.
ONCOLOGY REPORTS (2016)
Combination Approaches with immune-Checkpoint Blockade in Cancer Therapy
Maarten Swart et al.
FRONTIERS IN ONCOLOGY (2016)
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
Jin Peng et al.
CANCER RESEARCH (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity
Kea Martin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L. Bracci et al.
CELL DEATH AND DIFFERENTIATION (2014)
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
Jedd D. Wolchok et al.
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN USA 2012 (2013)
Eradication of non-Hodgkin lymphoma through the induction of tumor-specific T-cell immunity by CD20-Flex BiFP
Lei Zhao et al.
BLOOD (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer et al.
CANCER RESEARCH (2009)
Cytotoxic T cells
Mads Hald Andersen et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
分享论文
